Business Wire

Eurofins, the global leader in analytical testing, expands worldwide face mask testing & certification capabilities

Share

Since the start of the pandemic Eurofins  (Paris:ERF) has tested thousands of models of surgical and hygienic masks and provided best-in-class speed and certification for PPEs globally, enabling these critical products to get market as fast as possible. Eurofins has developed global leading testing capabilities and certification services in the North America, Europe and Asia ensuring that PPE manufacturers are able to provide the indispensable support needed in the fight against the coronavirus.

As of today, Eurofins is one of the few GLP certified and ISO/IEC 17025 accredited laboratory networks to fully cover all testing requirements for surgical/medical and hygienic masks by the FDA, EU regulations and many international and country-specific directives and guidelines such as CEN, CE Marking, ISO, ASTM or OECD. Our robust portfolio for masks includes globally accepted, safety and performance testing, virucidal, bacterial filtration, particle filtration, differential pressure, biocompatibility, stability, splash resistance and flammability testing where required.

Eurofins is one of the very few testing service providers having developed 0.1 micron PFE (Particle Filtration Efficiency) capabilities to fulfil US regulatory expectations.

Beyond testing and certification services, Eurofins goes the extra mile with “Maskné” testing or skin tolerance studies, documentary review, safety and efficacy claim substantiation.

Eurofins’ highly skilled technical experts also provide assessment and support to manufacturers, importers, retailers and brand owners in ensuring the functionality and safety of masks, adapting the sampling methodology and testing protocols to the country-specific or certification requirements outlined in the standards of the international markets where the products are intended to be distributed.

For more information about the types of masks and their respective scope of compliance, please visit our website www.eurofins.com/COVID-19-product-testing or contact Eurofins’ local experts.

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Contact information

Miguel Ángel QUILES GRANADO
E-mail: CPT_marketing@eurofins.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Moody’s Analytics Wins Five InsuranceERM Awards1.3.2021 14:48:00 CETPress release

For the second straight year, Moody’s Analytics has won five categories in the InsuranceERM Awards: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210301005550/en/ » ERM End-to-End Solution of the Year » Economic Scenario Generator Software of the Year » Regulatory Reporting Software of the Year » Solvency II Solution of the Year » Stress Scenarios Software of the Year “Our insurance customers have had to address unparalleled, often unforeseeable changes in the last year. Throughout this period of uncertainty they have trusted Moody’s Analytics to help them achieve their goals,” said Colin Holmes, General Manager of Insurance Solutions. “We’re proud to have earned that trust and recognize that many other challenges lie ahead—including climate change and upcoming go-live for IFRS 17 and LDTI. As this recognition from InsuranceERM shows, our broad offering equips our insurance customers to be ready for whatever hurdles may ari

LFB Announces that the European Medicines Agency (EMA) Has Accepted for Filing the Marketing Authorization Application for eptacog beta (activated), a Recombinant Coagulation Factor VIIa1.3.2021 14:00:00 CETPress release

Regulatory News: LFB today announced that the European Medicines Agency (EMA), the European regulatory authority, has accepted for filing the Marketing Authorization Application for eptacog beta, a recombinant coagulation Factor VIIa (rFVIIa). The application includes data from three prospective phase 3 clinical trials (PERSEPT1, PERSEPT2, and PERSEPT3) assessing the efficacy and safety of eptacog beta in the treatment of bleeding episodes in children and adults with congenital haemophilia A or B with inhibitors and for the prevention of bleeding in those patients undergoing surgery or invasive procedures. The final outcome from the EMA review is expected by mid-2022. This announcement comes less than a year after the approval in April 2020 by the United States Food and Drug Administration (FDA) of LFB’s Biologics License Application (BLA) for the coagulation factor VIIa (recombinant)-jncw (eptacog beta), under the name SEVENFACT®, for the treatment and control of bleeding episodes occ

NetApp Joins Aston Martin Cognizant Formula One Team to Pioneer Data-Driven Racing Strategy1.3.2021 14:00:00 CETPress release

NetApp® (NASDAQ: NTAP), a global cloud-led, data-centric software company, and Aston Martin Cognizant Formula One™ today announced a multi-year partnership as the world-famous car company gears up for its return to Formula One competition. After more than 60 years away, the British car brand returns to the F1™ grid, supported by NetApp, with a new edge: an innovative approach to racing utilizing the power of data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210301005160/en/ NetApp Joins Aston Martin Cognizant Formula One Team to Pioneer Data-Driven Racing Strategy (Graphic: Business Wire) The partnership with NetApp reinforces Aston Martin Cognizant Formula One Team’s commitment to unlocking the very best of cloud by outfitting the team with world-class data and cloud services. Broad and ambitious in scope, the partnership will focus on maximizing performance both on and off the track. From trackside to factory to cloud,

Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity1.3.2021 14:00:00 CETPress release

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. This new collaboration builds on the positive experience from previous partnerships with Gubra and combines Gubra’s proprietary streaMLine platform and expertise in obesity and peptide chemistry with Boehringer Ingelheim’s expertise in lead optimization and clinical development. The companies share the goal of providing new obesity therapies with increased tolerability that support greater weight loss than current therapy options. “This marks the third joint research program between Boehringer Ingelheim and Gubra in the area of obesity since 2017,” said Søren Tullin, Ph.D., Senior Vice President and Global Head of Cardiometabolic Diseases Research, Boehringer Ingelheim. “We’re delighted to expand our established working relationship and proven track record with Gubra to uncover next-g

Hologic Acquires European Molecular Diagnostic Company Diagenode for Approximately $159 Million1.3.2021 13:00:00 CETPress release

Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that it has acquired Diagenode, a privately held, European developer and manufacturer of molecular diagnostic assays and epigenetics products, for approximately $159 million (130 million euros), subject to working capital and other customary closing adjustments. “Acquiring Diagenode further strengthens our molecular diagnostics business by expanding our international capabilities, improving our regional time-to-market, and allowing us to offer a broader, more differentiated test menu,” said Jan Verstreken, Hologic’s group president, international. “Diagenode has been a great partner since 2016, helping us develop and manufacture PCR-based assays for Panther Fusion®. Now we look forward to accelerating and broadening those efforts to benefit our customers and patients.” Diagenode offers more than 30 real-time PCR (polymerase chain reaction) tests that are CE-marked for the detection of bacteria, parasites a

Mouser Electronics Releases New Intelligent Revolution eBook Examining AI in Humanitarian Applications1.3.2021 13:00:00 CETPress release

Mouser Electronics Inc. today released Artificial Intelligence: Improving Harvests and the Human Experience, the third eBook from The Intelligent Revolution series. The new eBook examines fascinating new uses for artificial intelligence (AI) in farming and other specialised applications targeting the human experience. Mouser’s AI-focused eBook series is part of the company’s award-winning Empowering Innovation Together program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210301005097/en/ Mouser Electronics announces the third eBook from The Intelligent Revolution series, which examines fascinating new uses for AI in farming and other applications to improve the human experience. (Graphic: Business Wire) “While many are familiar with some common uses for artificial intelligence, innovative scientists around the world are constantly finding new applications,” said Kevin Hess, Senior Vice President, Marketing at Mouser Elect

Market Survey by TSUNO Group Reveals “Rice Bran Oil” Market in Japan Is Expanding Under COVID-19 Pandemic1.3.2021 11:35:00 CETPress release

TSUNO Group (HQ: Wakayama, Japan https://www.tsuno.co.jp) surveys the sales figure of edible vegetable oils and rice bran oil in Japan. (Data of The Nikkei 64 major chains stores and 461 stores in Japan March to May result based on total sales). As a result, the market of Rice Bran Oil for household use has expanded by 42% compared to the previous year. While the vegetable oil sales increased by 11% from previous year, rice bran oil and sesame oil sales grew by 42% during a state of emergency in Japan. The rapid expansion of these two oils could be explained by a rise in people’s health-consciousness under COVID-19 pandemic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210301005397/en/ TSUNO brand rice bran oils sized from 180g to 1500g. Full nutrients from rice bran are contained. Rice Bran Oil has strong anti oxidant effect and its healthy and goes well with any kind of dishes from dressing to deep fries. (Photo: Busines

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom